Insider transactions

EDGAR

STAAR SURGICAL CO

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-19.

Open-market purchases (code P)
22 transactions, 2,604,351 shares
Sum of shares × price per share: 62,750,663.817 11 without a price are not valued.
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 127

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-08-14 Filed 2026-08-18ANDREWS DEBORAH J Officer: Chief Financial Officer EVP
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)5,2330—41,452Direct (D) No— Open filing 0001325697-26-000011 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18ANDREWS DEBORAH J Officer: Chief Financial Officer EVP
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)2,66226.18
69,691.16

Derived: shares × price per share. Exact value 69691.16.

38,910Direct (D) No
F1
  • F1 On May 15, 2026, the third tranche of 5,233 performance stock units (PSUs) awarded to the Reporting Person under the 2025 PSU Program in connection with her new hire grant vested, of which 2,662 shares were withheld to satisfy taxes.
Open filing 0001325697-26-000011 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18ANDREWS DEBORAH J Officer: Chief Financial Officer EVP
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (4,975) — exercise price 0
Acquired (A)4,9750—4,975Direct (D) No
F2, F3, F4
  • F2 Each restricted stock unit (RSU) represents the right to receive one share of STAAR Surgical Company (Company) common stock upon vesting.
  • F3 The Reporting Person was granted Company RSUs on August 14, 2026 (the Grant Date). These RSUs vest as to one-third on the first anniversary of the Grant Date, and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.
  • F4 The Reporting Person was granted Issuer restricted stock units (RSUs) on August 14, 2026 (the Grant Date). These RSUs vest as to one-third on the first anniversary of the Grant Date, and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.
Open filing 0001325697-26-000011 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18ANDREWS DEBORAH J Officer: Chief Financial Officer EVP
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (8,952) — exercise price 26.18
Acquired (A)8,9520—8,952Direct (D) No
F5
  • F5 The Reporting Person was granted an option to purchase 8,952 shares of Company common stock. The shares underlying the option vest over three years from the Grant Date, with one-third vesting on the first anniversary of the Grant Date and the remaining two-thirds vesting in 24 substantially equal monthly installment thereafter.
Open filing 0001325697-26-000011 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18ANDREWS DEBORAH J Officer: Chief Financial Officer EVP
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Performance Stock Option (right to buy) — underlying Common Stock (29,159) — exercise price 26.18
Acquired (A)29,1590—29,159Direct (D) No
F6
  • F6 The Reporting Person was granted a performance option to purchase 29,159 shares of Company common stock. The shares underlying the option vest over a performance period ending on the earlier of a change in control and the 10-year anniversary of the Grant Date, subject to achievement of stock-price hurdles of $50.00, $75.00 and $100.00 per share, and time vest as to one-third on the anniversary of the Grant Date with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.
Open filing 0001325697-26-000011 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18ANDREWS DEBORAH J Officer: Chief Financial Officer EVP
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Performance Stock Units — underlying Common Stock (5,233) — exercise price 0
Acquired (A)5,2330—41,452Direct (D) No
F7
  • F7 Represents the settlement of the third tranche of PSUs awarded to the Reporting Person in connection with her new hire grant under the 2025 PSU Program. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.
Open filing 0001325697-26-000011 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Foust Warren Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)7,3310—93,887Direct (D) No— Open filing 0001970778-26-000014 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Foust Warren Officer: President and CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)3,73026.18
97,651.4

Derived: shares × price per share. Exact value 97651.40.

97,617Direct (D) No
F1
  • F1 On August 14, 2026, the third tranche of 7,331 performance stock units (PSUs) awarded to the Reporting Person under the Issuer's 2025 Performance Stock Award Program (2025 PSU Program) in connection with his annual equity grant vested, of which 3,730 shares were withheld to satisfy taxes.
Open filing 0001970778-26-000014 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Foust Warren Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,6660—93,951Direct (D) No— Open filing 0001970778-26-000014 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Foust Warren Officer: President and CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,86526.18
48,825.7

Derived: shares × price per share. Exact value 48825.70.

95,816Direct (D) No
F2
  • F2 On August 14, 2026, the third tranche of 3,666 PSUs awarded to the Reporting Person under the Issuer's 2025 PSU Program in connection with his expanded role as President and Chief Operating Officer vested, of which 1,865 shares were withheld to satisfy taxes.
Open filing 0001970778-26-000014 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Foust Warren Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (22,493) — exercise price 0
Acquired (A)22,4930—22,493Direct (D) No
F3, F4
  • F3 Each RSU represents the right to receive one share of the Corporation's common stock upon vesting.
  • F4 The Reporting Person was granted Issuer restricted stock units (RSUs) on August 14, 2026 (the Grant Date). These RSUs vest as to 1/3 on the first anniversary of the Grant Date, and the remaining 2/3 vesting in 24 substantially equal monthly installments thereafter.
Open filing 0001970778-26-000014 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Foust Warren Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (40,471) — exercise price 26.18
Acquired (A)40,4710—40,471Direct (D) No
F5
  • F5 The Reporting Person was granted an option to purchase 40,471 shares of Company common stock. The shares underlying the option vest over three years from the Grant Date, with one-third vesting on the first anniversary of the Grant Date and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter
Open filing 0001970778-26-000014 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Foust Warren Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (37,962) — exercise price 26.18
Acquired (A)37,9620—37,962Direct (D) No
F6
  • F6 The Reporting Person was granted an option to purchase 37,962 shares of Company common stock. The shares underlying the option vest over 42 months from the Grant Date, with one-third vesting on the 18-month anniversary of the Grant Date and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.
Open filing 0001970778-26-000014 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Foust Warren Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Performance Stock Option (right to buy) — underlying Common Stock (131,830) — exercise price 26.18
Acquired (A)131,8300—131,830Direct (D) No
F7
  • F7 The Reporting Person was granted a performance option to purchase 131,830 shares of Company common stock. The shares underlying the option vest over a performance period ending on the earlier of a change in control and the 10-year anniversary of the Grant Date, subject to achievement of stock-price hurdles of $50.00, $75.00 and $100.00 per share, and time vest as to one-third on the first anniversary of the Grant Date with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.
Open filing 0001970778-26-000014 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Foust Warren Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Performance Stock Option (right to buy) — underlying Common Stock (123,659) — exercise price 26.18
Acquired (A)123,6590—123,659Direct (D) No
F8
  • F8 The Reporting Person was granted a performance option to purchase 123,659 shares of Company common stock. The shares underlying the option vest over a performance period ending on the earlier of a change in control and the 10-year anniversary of the Grant Date, subject to achievement of stock-price hurdles of $50.00, $75.00 and $100.00 per share, and time vest as to one-third on the 18-month anniversary of the Grant Date with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.
Open filing 0001970778-26-000014 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Foust Warren Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Performance Stock Units — underlying Common Stock (7,331) — exercise price 0
Acquired (A)7,3310—93,887Direct (D) No
F9
  • F9 Represents the settlement of the third tranche of PSUs awarded to the Reporting Person in connection with his annual equity grant under the 2025 PSU Program. The number of shares was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.
Open filing 0001970778-26-000014 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Foust Warren Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Performance Stock Units — underlying Common Stock (3,666) — exercise price 0
Acquired (A)3,6660—97,553Direct (D) No
F10
  • F10 Represents the settlement of the third tranche of PSUs awarded under the 2025 PSU Program to the Reporting Person in connection with his expanded role as President Chief Operating Officer. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.
Open filing 0001970778-26-000014 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Michna Magda Officer: Chief Development Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)5,4990—43,599Direct (D) No
F1
  • F1 Due to clerical errors, the Reporting Person's prior Form-4 filed with the Securities and Exchange Commission on May 12, 2026 incorrectly reported this value as 32,691 shares when the Reporting Person beneficially owned 28,008 shares and the Reporting Person's prior Form 4 filed with the SEC on May 19, 2026 incorrectly reported this value as 46,026 when the Reporting Person beneficially owned 38.100. The values have been corrected herein.
Open filing 0001731487-26-000011 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Michna Magda Officer: Chief Development Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)2,79726.18
73,225.46

Derived: shares × price per share. Exact value 73225.46.

40,802Direct (D) No
F2
  • F2 On August 14, 2026, the third tranche of 5,499 performance stock units (PSUs) awarded to the Reporting Person under the Issuer's 2025 Performance Stock Award Program (2025 PSU Program) in connection with her annual equity grant vested, of which 2,797 shares were withheld to satisfy taxes.
Open filing 0001731487-26-000011 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Michna Magda Officer: Chief Development Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)55926.18
14,634.62

Derived: shares × price per share. Exact value 14634.62.

40,243Direct (D) No— Open filing 0001731487-26-000011 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Michna Magda Officer: Chief Development Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)1,10026.18
28,798

Derived: shares × price per share. Exact value 28798.00.

41,343Direct (D) No— Open filing 0001731487-26-000011 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Michna Magda Officer: Chief Development Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Performance Stock Units — underlying Common Stock (5,499) — exercise price 0
Acquired (A)5,4990—5,499Direct (D) No
F3
  • F3 Represents the settlement of the third tranche of 5,499 PSUs awarded to the Reporting Person under the Issuer's 2025 PSU Program in connection with her annual equity grant vested. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.
Open filing 0001731487-26-000011 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Michna Magda Officer: Chief Development Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Performance Stock Units — underlying Common Stock (1,100) — exercise price 0
Acquired (A)1,1000—1,100Direct (D) No
F4
  • F4 Represents the settlement of the third tranche of of 1,100 PSUs awarded to the Reporting Person under the Issuer's 2025 PSU Program in connection with her promotion to Chief Development Officer vested. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.
Open filing 0001731487-26-000011 Read from the filing’s XML Dispute this row
2026-07-31 Filed 2026-08-04ANDREWS DEBORAH J Officer: Chief Financial Officer EVP
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)20,787——46,915Direct (D) No
F2
  • F2 Represents the vesting of RSUs granted to the Reporting Person on February 2, 2026, in connection with the Reporting Person's appointment as Interim Co-Chief Executive Officer of the Issuer on such date. The RSUs vested on July 31, 2026. The RSUs convert into common stock on a one-for-one basis.
Open filing 0001325697-26-000009 Read from the filing’s XML Dispute this row
2026-07-31 Filed 2026-08-04ANDREWS DEBORAH J Officer: Chief Financial Officer EVP
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)10,57624.36
257,631.36

Derived: shares × price per share. Exact value 257631.36.

36,339Direct (D) No— Open filing 0001325697-26-000009 Read from the filing’s XML Dispute this row
2026-07-31 Filed 2026-08-04ANDREWS DEBORAH J Officer: Chief Financial Officer EVP
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (20,787)
Disposed (D)20,7870—0Direct (D) No
F2
  • F2 Represents the vesting of RSUs granted to the Reporting Person on February 2, 2026, in connection with the Reporting Person's appointment as Interim Co-Chief Executive Officer of the Issuer on such date. The RSUs vested on July 31, 2026. The RSUs convert into common stock on a one-for-one basis.
Open filing 0001325697-26-000009 Read from the filing’s XML Dispute this row
2026-07-31 Filed 2026-08-04Foust Warren Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)20,787——97,132Direct (D) No
F1, F2
  • F1 Represents the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 2, 2026, in connection with his appointment as Interim Co-Chief Executive Officer of the Issuer on such date. These RSUs vested on July 31, 2026. The RSUs convert into common stock on a one-for-one basis.
  • F2 Due to clerical errors, the Reporting Person's prior Form 4 filed with the Securities and Exchange Commission on May 19, 2026, incorrectly reported this value as 83,112 when the Reporting Person beneficially owned 76,345 shares. The values have been corrected herein.
Open filing 0001970778-26-000012 Read from the filing’s XML Dispute this row
2026-07-31 Filed 2026-08-04Foust Warren Officer: President and CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)10,57624.36
257,631.36

Derived: shares × price per share. Exact value 257631.36.

86,556Direct (D) No— Open filing 0001970778-26-000012 Read from the filing’s XML Dispute this row
2026-07-31 Filed 2026-08-04Foust Warren Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (20,787)
Disposed (D)20,7870—0Direct (D) No
F1
  • F1 Represents the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 2, 2026, in connection with his appointment as Interim Co-Chief Executive Officer of the Issuer on such date. These RSUs vested on July 31, 2026. The RSUs convert into common stock on a one-for-one basis.
Open filing 0001970778-26-000012 Read from the filing’s XML Dispute this row
2026-06-25 Filed 2026-08-04ANDREWS DEBORAH J Officer: Chief Financial Officer EVP
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)13,955——32,608Direct (D) No
F1
  • F1 Represents the vesting of restricted stock units (RSUs) granted to the Reporting Person on June 25, 2025, in connection with her appointment as Chief Financial Officer of the Issuer on such date. These RSUs vest as to 1/3 of the shares subject to the award on each of June 25, 2026, 2027 and 2028. The RSUs convert into common stock on a one-for-one basis.
Open filing 0001325697-26-000009 Read from the filing’s XML Dispute this row
2026-06-25 Filed 2026-08-04ANDREWS DEBORAH J Officer: Chief Financial Officer EVP
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)6,48031.21
202,240.8

Derived: shares × price per share. Exact value 202240.80.

26,128Direct (D) No— Open filing 0001325697-26-000009 Read from the filing’s XML Dispute this row
2026-06-25 Filed 2026-08-04ANDREWS DEBORAH J Officer: Chief Financial Officer EVP
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (13,955)
Disposed (D)13,9550—27,912Direct (D) No
F1
  • F1 Represents the vesting of restricted stock units (RSUs) granted to the Reporting Person on June 25, 2025, in connection with her appointment as Chief Financial Officer of the Issuer on such date. These RSUs vest as to 1/3 of the shares subject to the award on each of June 25, 2026, 2027 and 2028. The RSUs convert into common stock on a one-for-one basis.
Open filing 0001325697-26-000009 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-23Wang Christopher Min Fang Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Common Stock Option — underlying Common Stock, par value $0.01 per share (11,145) — exercise price 29.12
Acquired (A)11,1450—11,145Direct (D) No
F1
  • F1 Award of stock options granted to the Reporting Person on June 18, 2026. These stock options will vest in full on the earlier of June 18, 2027 or the Issuer's 2026 annual meeting of shareholders.
Open filing 0000921895-26-001649 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Butcher Arthur C Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)5,3410—9,549Direct (D) No
F1
  • F1 Reflects restricted stock units granted to the Reporting Person on June 18, 2025, pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term, which vested on June 18, 2026.
Open filing 0001678249-26-000003 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Butcher Arthur C Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (5,341) — exercise price 0
Disposed (D)5,3410—0Direct (D) No
F1
  • F1 Reflects restricted stock units granted to the Reporting Person on June 18, 2025, pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term, which vested on June 18, 2026.
Open filing 0001678249-26-000003 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Butcher Arthur C Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Common Stock Options — underlying Common Stock (4,458) — exercise price 29.12
Acquired (A)4,4580—4,458Direct (D) No
F2
  • F2 Reflects restricted stock units and options to purchase common stock granted to the Reporting Person on June 18, 2026, pursuant to the Issuer's annual non-employee director equity compensation program for the 2026-2027 term. These equity awards vest in full on the earlier of June 18, 2027 or the Issuer's 2027 Annual Meeting of Shareholders.
Open filing 0001678249-26-000003 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Butcher Arthur C Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (3,709) — exercise price 0
Acquired (A)3,7090—3,709Direct (D) No
F2
  • F2 Reflects restricted stock units and options to purchase common stock granted to the Reporting Person on June 18, 2026, pursuant to the Issuer's annual non-employee director equity compensation program for the 2026-2027 term. These equity awards vest in full on the earlier of June 18, 2027 or the Issuer's 2027 Annual Meeting of Shareholders.
Open filing 0001678249-26-000003 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Jiang Wei Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)10,6830—77,127Direct (D) No
F1
  • F1 Reflects restricted stock units granted to the Reporting Person on June 18, 2025, pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term, which vested on June 18, 2026.
Open filing 0001867980-26-000006 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Jiang Wei Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (10,683) — exercise price 0
Disposed (D)10,6830—0Direct (D) No
F1
  • F1 Reflects restricted stock units granted to the Reporting Person on June 18, 2025, pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term, which vested on June 18, 2026.
Open filing 0001867980-26-000006 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Jiang Wei Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (6,182) — exercise price 0
Acquired (A)6,1820—6,182Direct (D) No
F2
  • F2 Reflects restricted stock units granted to the Reporting Person on June 18, 2026, pursuant to the Issuer's annual non-employee director equity compensation program for the 2026-2027 term. These equity awards vest in full on the earlier of June 18, 2027 or the Issuer's 2027 Annual Meeting of Shareholders.
Open filing 0001867980-26-000006 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Zhou Lilian Yansheng Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (3,091) — exercise price 0
Acquired (A)3,0910—3,091Direct (D) No
F1
  • F1 Reflects restricted stock units and options to purchase common stock granted to the Reporting Person on June 18, 2026, pursuant to the Issuer's annual non-employee director equity compensation program for the 2026-2027 term. These equity awards vest in full on the earlier of June 18, 2027 or the Issuer's 2027 Annual Meeting of Shareholders.
Open filing 0002003105-26-000005 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Zhou Lilian Yansheng Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Common Stock Options — underlying Common Stock (5,572) — exercise price 29.12
Acquired (A)5,5720—5,572Direct (D) No
F1
  • F1 Reflects restricted stock units and options to purchase common stock granted to the Reporting Person on June 18, 2026, pursuant to the Issuer's annual non-employee director equity compensation program for the 2026-2027 term. These equity awards vest in full on the earlier of June 18, 2027 or the Issuer's 2027 Annual Meeting of Shareholders.
Open filing 0002003105-26-000005 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22LeBuhn Richard T. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: OPTION TO PURCHASE COMMON STOCK — underlying COMMON STOCK (11,145) — exercise price 29.12
Acquired (A)11,1450—11,145Direct (D) No
F2, F1
  • F2 These options were granted to the Reporting Person by the Issuer on June 18, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended.
  • F1 These options will vest and become exercisable on the earlier of: (a) June 18, 2027 and (b) the date of STAAR Surgical Company's (the Issuer) next annual meeting of shareholders after the grant date, subject, in each case, to Richard T. LeBuhn's (the Reporting Person) continuous service with the Issuer.
Open filing 0000919574-26-004069 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Bradsher Neal C Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: OPTION TO PURCHASE COMMON STOCK — underlying COMMON STOCK (11,145) — exercise price 29.12
Acquired (A)11,1450—11,145Direct (D) No
F2, F1
  • F2 These options were granted to the Reporting Person by the Issuer on June 18, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended.
  • F1 These options will vest and become exercisable on the earlier of: (a) June 18, 2027 and (b) the date of STAAR Surgical Company's (the Issuer) next annual meeting of shareholders after the grant date, subject, in each case, to Neal C. Bradsher's (the Reporting Person) continuous service with the Issuer.
Open filing 0000919574-26-004068 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22SILVERMAN LOU Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)10,6830—11,158Direct (D) No
F1
  • F1 Reflects restricted stock units granted to the Reporting Person on June 18, 2025, pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term, which vested on June 18, 2026.
Open filing 0001249935-26-000004 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22SILVERMAN LOU Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (10,683) — exercise price 0
Disposed (D)10,6830—0Direct (D) No
F1
  • F1 Reflects restricted stock units granted to the Reporting Person on June 18, 2025, pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term, which vested on June 18, 2026.
Open filing 0001249935-26-000004 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22SILVERMAN LOU Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (6,182) — exercise price 0
Acquired (A)6,1820—6,182Direct (D) No
F2
  • F2 Reflects restricted stock units granted to the Reporting Person on June 18, 2026, pursuant to the Issuer's annual non-employee director equity compensation program for the 2026-2027 term. These equity awards vest in full on the earlier of June 18, 2027 or the Issuer's 2027 Annual Meeting of Shareholders.
Open filing 0001249935-26-000004 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-15Zhou Lilian Yansheng Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3,53028.2904
99,865.112

Derived: shares × price per share. Exact value 99865.1120.

8,101Direct (D) No
F1
  • F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.215 to $28.35, inclusive.
Open filing 0001193125-26-271092 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19Michna Magda Officer: Chief Development Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)10,9970—43,688Direct (D) No— Open filing 0001731487-26-000008 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19Michna Magda Officer: Chief Development Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)5,59532.07
179,431.65

Derived: shares × price per share. Exact value 179431.65.

38,093Direct (D) No
F1
  • F1 On May 15, 2026, the first tranche of 10,997 performance stock units (PSUs) awarded to the Reporting Person under the Issuer's 2025 Performance Stock Unit Award Program (2025 PSU Program) in connection with her annual equity grant vested, of which 5,595 shares were withheld to satisfy taxes .
Open filing 0001731487-26-000008 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Point72 Asset Management, L.P. Common Stock, par value $0.01 per share1.6819,979.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-008100 Dispute this row
Point72 Capital Advisors, Inc. Common Stock, par value $0.01 per share1.6819,979.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-008100 Dispute this row
Steven A. Cohen Common Stock, par value $0.01 per share1.6819,979.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-008100 Dispute this row
Madison Avenue International LP Common Stock, par value $0.01 per share (the "Common Stock")9.74,891,99509/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001013594-26-001192 Dispute this row
Madison Avenue Partners, LP Common Stock, par value $0.01 per share (the "Common Stock")9.74,891,99509/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001013594-26-001192 Dispute this row
EMAI Management, LLC Common Stock, par value $0.01 per share (the "Common Stock")9.74,891,99509/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001013594-26-001192 Dispute this row
Madison Avenue GP, LLC Common Stock, par value $0.01 per share (the "Common Stock")9.74,891,99509/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001013594-26-001192 Dispute this row
Caraway Jackson Investments LLC Common Stock, par value $0.01 per share (the "Common Stock")9.74,891,99509/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001013594-26-001192 Dispute this row
Eli Samaha Common Stock, par value $0.01 per share (the "Common Stock")9.74,891,99509/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001013594-26-001192 Dispute this row
BlackRock, Inc. Common Stock9.24,611,82709/30/2026 Filed 2026-10-27SCHEDULE 13G/AAmendment 20Open filing 0002012383-26-003941 Dispute this row
Madison Avenue International LP Common Stock, par value $0.01 per share (the "Common Stock")8.44,175,74806/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001013594-26-000899 Dispute this row
Madison Avenue Partners, LP Common Stock, par value $0.01 per share (the "Common Stock")8.44,175,74806/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001013594-26-000899 Dispute this row
EMAI Management, LLC Common Stock, par value $0.01 per share (the "Common Stock")8.44,175,74806/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001013594-26-000899 Dispute this row
Madison Avenue GP, LLC Common Stock, par value $0.01 per share (the "Common Stock")8.44,175,74806/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001013594-26-000899 Dispute this row
Caraway Jackson Investments LLC Common Stock, par value $0.01 per share (the "Common Stock")8.44,175,74806/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001013594-26-000899 Dispute this row
Eli Samaha Common Stock, par value $0.01 per share (the "Common Stock")8.44,175,74806/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001013594-26-000899 Dispute this row
Point72 Asset Management, L.P. Common Stock, par value $0.01 per share5.22,591,498.0005/11/2026 Filed 2026-05-12SCHEDULE 13GOpen filing 0000919574-26-002872 Dispute this row
Point72 Capital Advisors, Inc. Common Stock, par value $0.01 per share5.22,591,498.0005/11/2026 Filed 2026-05-12SCHEDULE 13GOpen filing 0000919574-26-002872 Dispute this row
Steven A. Cohen Common Stock, par value $0.01 per share5.22,591,498.0005/11/2026 Filed 2026-05-12SCHEDULE 13GOpen filing 0000919574-26-002872 Dispute this row
Madison Avenue International LP Common Stock, par value $0.01 per share (the "Common Stock")5.82,854,71004/13/2026 Filed 2026-04-20SCHEDULE 13GOpen filing 0001013594-26-000466 Dispute this row
Madison Avenue Partners, LP Common Stock, par value $0.01 per share (the "Common Stock")5.82,854,71004/13/2026 Filed 2026-04-20SCHEDULE 13GOpen filing 0001013594-26-000466 Dispute this row
EMAI Management, LLC Common Stock, par value $0.01 per share (the "Common Stock")5.82,854,71004/13/2026 Filed 2026-04-20SCHEDULE 13GOpen filing 0001013594-26-000466 Dispute this row
Madison Avenue GP, LLC Common Stock, par value $0.01 per share (the "Common Stock")5.82,854,71004/13/2026 Filed 2026-04-20SCHEDULE 13GOpen filing 0001013594-26-000466 Dispute this row
Caraway Jackson Investments LLC Common Stock, par value $0.01 per share (the "Common Stock")5.82,854,71004/13/2026 Filed 2026-04-20SCHEDULE 13GOpen filing 0001013594-26-000466 Dispute this row
Eli Samaha Common Stock, par value $0.01 per share (the "Common Stock")5.82,854,71004/13/2026 Filed 2026-04-20SCHEDULE 13GOpen filing 0001013594-26-000466 Dispute this row
BlackRock, Inc. Common Stock13.16,507,91103/31/2026 Filed 2026-04-24SCHEDULE 13G/AAmendment 19Open filing 0002012383-26-001515 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-27SCHEDULE 13G/AAmendment 8Open filing 0000102909-26-002338 Dispute this row
Broadwood Partners, L.P. Common Stock, par value $0.01 per share32.616,123,842.0003/13/2026 Filed 2026-03-13SCHEDULE 13D/AAmendment 44Open filing 0000919574-26-001619 Dispute this row
Broadwood Capital, Inc. Common Stock, par value $0.01 per share32.616,123,842.0003/13/2026 Filed 2026-03-13SCHEDULE 13D/AAmendment 44Open filing 0000919574-26-001619 Dispute this row
Neal C. Bradsher Common Stock, par value $0.01 per share32.616,149,742.0003/13/2026 Filed 2026-03-13SCHEDULE 13D/AAmendment 44Open filing 0000919574-26-001619 Dispute this row
Richard T. LeBuhn Common Stock, par value $0.01 per share0.021,286.0003/13/2026 Filed 2026-03-13SCHEDULE 13D/AAmendment 44Open filing 0000919574-26-001619 Dispute this row
Yunqi Path Capital Master Fund Common Stock, par value $0.01 per share5.22,575,061.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 7Open filing 0000921895-26-000097 Dispute this row
Yunqi Capital Limited Common Stock, par value $0.01 per share6.53,257,130.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 7Open filing 0000921895-26-000097 Dispute this row
Yunqi Capital Cayman Limited Common Stock, par value $0.01 per share6.53,257,130.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 7Open filing 0000921895-26-000097 Dispute this row
Christopher Min Fang Wang Common Stock, par value $0.01 per share6.53,257,130.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 7Open filing 0000921895-26-000097 Dispute this row
Yunqi China Special Investment A Common Stock, par value $0.01 per share1.4682,069.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 7Open filing 0000921895-26-000097 Dispute this row
HS Group Master Fund II Ltd Common Stock, par value $0.01 per share1.4682,069.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 7Open filing 0000921895-26-000097 Dispute this row
HS Group (Hong Kong) Limited Common Stock, par value $0.01 per share1.4682,069.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 7Open filing 0000921895-26-000097 Dispute this row
HS Group Ltd Common Stock, par value $0.01 per share1.4682,069.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 7Open filing 0000921895-26-000097 Dispute this row
Broadwood Partners, L.P. Common Stock, par value $0.01 per share31.115,453,629.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 43Open filing 0001213900-26-005310 Dispute this row
Broadwood Capital, Inc. Common Stock, par value $0.01 per share31.115,453,629.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 43Open filing 0001213900-26-005310 Dispute this row
Neal C. Bradsher Common Stock, par value $0.01 per share31.115,479,529.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 43Open filing 0001213900-26-005310 Dispute this row
Richard T. LeBuhn Common Stock, par value $0.01 per share0.021,286.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 43Open filing 0001213900-26-005310 Dispute this row
Natalie R. Capasso Common Stock, par value $0.01 per share00.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 43Open filing 0001213900-26-005310 Dispute this row
Raymond A. Myers Common Stock, par value $0.01 per share00.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 43Open filing 0001213900-26-005310 Dispute this row
Jason J. Martin Common Stock, par value $0.01 per share00.0001/14/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 43Open filing 0001213900-26-005310 Dispute this row
Yunqi Path Capital Master Fund Common Stock, par value $0.01 per share5.22,575,061.0001/06/2026 Filed 2026-01-08SCHEDULE 13D/AAmendment 6Open filing 0000921895-26-000058 Dispute this row
Yunqi Capital Limited Common Stock, par value $0.01 per share6.53,257,130.0001/06/2026 Filed 2026-01-08SCHEDULE 13D/AAmendment 6Open filing 0000921895-26-000058 Dispute this row
Yunqi Capital Cayman Limited Common Stock, par value $0.01 per share6.53,257,130.0001/06/2026 Filed 2026-01-08SCHEDULE 13D/AAmendment 6Open filing 0000921895-26-000058 Dispute this row
Christopher Min Fang Wang Common Stock, par value $0.01 per share6.53,257,130.0001/06/2026 Filed 2026-01-08SCHEDULE 13D/AAmendment 6Open filing 0000921895-26-000058 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,525,707 filings read, dated 2004-06-14 to 2026-11-18: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020166,957
2021249,835
2022216,725
2023229,674
2024234,045
2025235,520
2026262,403

Filings made before the SEC required XML are listed, not extracted.

Back to STAAR SURGICAL CO